These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 15930352

  • 1. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial.
    Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, Yoshida S, Abe T, Narita M, Takahashi M, Tanaka R.
    Clin Cancer Res; 2005 Jun 01; 11(11):4160-7. PubMed ID: 15930352
    [Abstract] [Full Text] [Related]

  • 2. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
    Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ.
    Cancer Res; 2004 Jul 15; 64(14):4973-9. PubMed ID: 15256471
    [Abstract] [Full Text] [Related]

  • 3. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
    Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R, Roman JJ, Burnett A, Pecorelli S, Cannon MJ.
    Gynecol Oncol; 2006 Mar 15; 100(3):469-78. PubMed ID: 16249018
    [Abstract] [Full Text] [Related]

  • 4. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.
    Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, Pietersz GA, Apostolopoulos V, Vaughan H, Karanikas V, Kyriakou P, McKenzie IF, Mitchell PL.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):869-77. PubMed ID: 16467101
    [Abstract] [Full Text] [Related]

  • 5. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.
    Yajima N, Yamanaka R, Mine T, Tsuchiya N, Homma J, Sano M, Kuramoto T, Obata Y, Komatsu N, Arima Y, Yamada A, Shigemori M, Itoh K, Tanaka R.
    Clin Cancer Res; 2005 Aug 15; 11(16):5900-11. PubMed ID: 16115932
    [Abstract] [Full Text] [Related]

  • 6. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas.
    Katano M, Morisaki T, Koga K, Nakamura M, Onishi H, Matsumoto K, Tasaki A, Nakashima H, Akiyoshi T, Nakamura M.
    Anticancer Res; 2005 Aug 15; 25(6A):3771-6. PubMed ID: 16302738
    [Abstract] [Full Text] [Related]

  • 7. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
    Chang GC, Lan HC, Juang SH, Wu YC, Lee HC, Hung YM, Yang HY, Whang-Peng J, Liu KJ.
    Cancer; 2005 Feb 15; 103(4):763-71. PubMed ID: 15637694
    [Abstract] [Full Text] [Related]

  • 8. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H, Zhou FJ, Wang QJ, Qin ZK, Huang LX, Liu ZW, Han H, Li YQ, Chen SP, Xia JC.
    Ai Zheng; 2006 May 15; 25(5):625-30. PubMed ID: 16687087
    [Abstract] [Full Text] [Related]

  • 9. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma.
    Chang CN, Huang YC, Yang DM, Kikuta K, Wei KJ, Kubota T, Yang WK.
    J Clin Neurosci; 2011 Aug 15; 18(8):1048-54. PubMed ID: 21715171
    [Abstract] [Full Text] [Related]

  • 10. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment.
    Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD.
    Clin Cancer Res; 2005 Aug 01; 11(15):5515-25. PubMed ID: 16061868
    [Abstract] [Full Text] [Related]

  • 11. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.
    Hegmans JP, Veltman JD, Lambers ME, de Vries IJ, Figdor CG, Hendriks RW, Hoogsteden HC, Lambrecht BN, Aerts JG.
    Am J Respir Crit Care Med; 2010 Jun 15; 181(12):1383-90. PubMed ID: 20167848
    [Abstract] [Full Text] [Related]

  • 12. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.
    Lesimple T, Neidhard EM, Vignard V, Lefeuvre C, Adamski H, Labarrière N, Carsin A, Monnier D, Collet B, Clapisson G, Birebent B, Philip I, Toujas L, Chokri M, Quillien V.
    Clin Cancer Res; 2006 Dec 15; 12(24):7380-8. PubMed ID: 17189411
    [Abstract] [Full Text] [Related]

  • 13. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.
    Van Driessche A, Van de Velde AL, Nijs G, Braeckman T, Stein B, De Vries JM, Berneman ZN, Van Tendeloo VF.
    Cytotherapy; 2009 Dec 15; 11(5):653-68. PubMed ID: 19530029
    [Abstract] [Full Text] [Related]

  • 14. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.
    Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, Yong WH, Incardona F, Thompson RC, Riedinger MS, Zhang W, Prins RM, Black KL.
    Cancer Res; 2001 Feb 01; 61(3):842-7. PubMed ID: 11221866
    [Abstract] [Full Text] [Related]

  • 15. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Dessureault S, Noyes D, Lee D, Dunn M, Janssen W, Cantor A, Sotomayor E, Messina J, Antonia SJ.
    Ann Surg Oncol; 2007 Feb 01; 14(2):869-84. PubMed ID: 17103257
    [Abstract] [Full Text] [Related]

  • 16. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
    Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, Hanaoka H, Shimizu N, Suzuki M, Yoshino I, Taniguchi M, Fujisawa T, Nakayama T.
    J Immunol; 2009 Feb 15; 182(4):2492-501. PubMed ID: 19201905
    [Abstract] [Full Text] [Related]

  • 17. Active immunotherapy for cancer patients using tumor lysate pulsed dendritic cell vaccine: a safety study.
    Ovali E, Dikmen T, Sonmez M, Yilmaz M, Unal A, Dalbasti T, Kuzeyli K, Erturk M, Omay SB.
    J Exp Clin Cancer Res; 2007 Jun 15; 26(2):209-14. PubMed ID: 17725100
    [Abstract] [Full Text] [Related]

  • 18. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients.
    Bedrosian I, Mick R, Xu S, Nisenbaum H, Faries M, Zhang P, Cohen PA, Koski G, Czerniecki BJ.
    J Clin Oncol; 2003 Oct 15; 21(20):3826-35. PubMed ID: 14551301
    [Abstract] [Full Text] [Related]

  • 19. Autologous natural killer cell therapy for human recurrent malignant glioma.
    Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T, Ohno T.
    Anticancer Res; 2004 Oct 15; 24(3b):1861-71. PubMed ID: 15274367
    [Abstract] [Full Text] [Related]

  • 20. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
    Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S, Niedzwiecki D, Panicali D, Schlom J, Lyerly HK.
    Clin Cancer Res; 2005 Apr 15; 11(8):3017-24. PubMed ID: 15837756
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.